🚀 VC round data is live in beta, check it out!
Kangmei Pharmaceutical Co. Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kangmei Pharmaceutical Co. and similar public comparables like Virbac, TransThera Sciences, Voronoi, Zhejiang Huahai and more.
Kangmei Pharmaceutical Co. Overview
About Kangmei Pharmaceutical Co.
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs, and medical devices, modern pharmaceutical logistics system. The company is also engaged in medical equipment, property leasing and sales, and other services.
Founded
1997
HQ
Employees
4.2K
Website
Sectors
Financials (FY)
EV
$3B
Kangmei Pharmaceutical Co. Financials
Kangmei Pharmaceutical Co. reported last fiscal year revenue of $760M and EBITDA of $58M.
In the same fiscal year, Kangmei Pharmaceutical Co. generated $112M in gross profit, $58M in EBITDA, and $1M in net income.
Kangmei Pharmaceutical Co. P&L
In the most recent fiscal year, Kangmei Pharmaceutical Co. reported revenue of $760M and EBITDA of $58M.
Kangmei Pharmaceutical Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $760M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $112M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA | — | XXX | $58M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 0% | XXX | XXX | XXX |
| Net Profit | — | XXX | $1M | XXX | XXX | XXX |
| Net Margin | — | XXX | 0% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kangmei Pharmaceutical Co. Stock Performance
Kangmei Pharmaceutical Co. has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Kangmei Pharmaceutical Co.'s stock price is $0.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | -0.5% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKangmei Pharmaceutical Co. Valuation Multiples
Kangmei Pharmaceutical Co. trades at 4.5x EV/Revenue multiple, and 58.4x EV/EBITDA.
Kangmei Pharmaceutical Co. Financial Valuation Multiples
As of April 14, 2026, Kangmei Pharmaceutical Co. has market cap of $4B and EV of $3B.
Equity research analysts estimate Kangmei Pharmaceutical Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kangmei Pharmaceutical Co. has a P/E ratio of 2822.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 58.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 903.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 30.2x | XXX | XXX | XXX |
| P/E | — | XXX | 2822.7x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (47.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kangmei Pharmaceutical Co. Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kangmei Pharmaceutical Co. Margins & Growth Rates
Kangmei Pharmaceutical Co.'s revenue in the last fiscal year grew by 6%.
Kangmei Pharmaceutical Co.'s revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
Kangmei Pharmaceutical Co. Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (23%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kangmei Pharmaceutical Co. Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kangmei Pharmaceutical Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Virbac | XXX | XXX | XXX | XXX | XXX | XXX |
| TransThera Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Voronoi | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Huahai | XXX | XXX | XXX | XXX | XXX | XXX |
| Kiniksa Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kangmei Pharmaceutical Co. M&A Activity
Kangmei Pharmaceutical Co. acquired XXX companies to date.
Last acquisition by Kangmei Pharmaceutical Co. was on XXXXXXXX, XXXXX. Kangmei Pharmaceutical Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kangmei Pharmaceutical Co.
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKangmei Pharmaceutical Co. Investment Activity
Kangmei Pharmaceutical Co. invested in XXX companies to date.
Kangmei Pharmaceutical Co. made its latest investment on XXXXXXXX, XXXXX. Kangmei Pharmaceutical Co. invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kangmei Pharmaceutical Co.
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kangmei Pharmaceutical Co.
| When was Kangmei Pharmaceutical Co. founded? | Kangmei Pharmaceutical Co. was founded in 1997. |
| Where is Kangmei Pharmaceutical Co. headquartered? | Kangmei Pharmaceutical Co. is headquartered in China. |
| How many employees does Kangmei Pharmaceutical Co. have? | As of today, Kangmei Pharmaceutical Co. has over 4K employees. |
| Is Kangmei Pharmaceutical Co. publicly listed? | Yes, Kangmei Pharmaceutical Co. is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Kangmei Pharmaceutical Co.? | Kangmei Pharmaceutical Co. trades under 600518 ticker. |
| When did Kangmei Pharmaceutical Co. go public? | Kangmei Pharmaceutical Co. went public in 2001. |
| Who are competitors of Kangmei Pharmaceutical Co.? | Kangmei Pharmaceutical Co. main competitors are Virbac, TransThera Sciences, Voronoi, Zhejiang Huahai. |
| What is the current market cap of Kangmei Pharmaceutical Co.? | Kangmei Pharmaceutical Co.'s current market cap is $4B. |
| What is the current revenue of Kangmei Pharmaceutical Co.? | Kangmei Pharmaceutical Co.'s last fiscal year revenue is $760M. |
| What is the current EV/Revenue multiple of Kangmei Pharmaceutical Co.? | Current revenue multiple of Kangmei Pharmaceutical Co. is 4.5x. |
| Is Kangmei Pharmaceutical Co. profitable? | No, Kangmei Pharmaceutical Co. is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.